• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cingulate Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders

    3/24/26 5:14:49 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CING alert in real time by email
    false 0001862150 0001862150 2026-03-24 2026-03-24 0001862150 CING:CommonStockParValue0.0001PerShareMember 2026-03-24 2026-03-24 0001862150 CING:WarrantsExercisableForOneShareOfCommonStockMember 2026-03-24 2026-03-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported):

    March 24, 2026

     

    CINGULATE INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-40874   86-3825535
    (State or other jurisdiction   (Commission   (IRS Employer
    of incorporation)   File Number)   Identification No.)

     

    1901 W. 47th Place

    Kansas City, KS 66205

    (Address of principal executive offices) (Zip Code)

     

    (913) 942-2300

    (Registrant’s telephone number, including area code)

     

     

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
       

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of exchange on which registered
    Common Stock, par value $0.0001 per share   CING  

    The Nasdaq Stock Market LLC

    (Nasdaq Capital Market)

    Warrants, exercisable for common stock   CINGW  

    The Nasdaq Stock Market LLC

    (Nasdaq Capital Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01. Entry Into a Material Definitive Agreement.

     

    On March 24, 2026, Cingulate Inc. (the “Company”) entered into an ATM Sales Agreement (the “ATM Agreement”) with A.G.P./Alliance Global Partners, as sales agent (“A.G.P.”), pursuant to which the Company may offer and sell, from time to time through A.G.P., shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), for aggregate gross proceeds of up to $100,000,000 (the “Placement Shares”). The offer and sale of the Placement Shares will be made pursuant to a shelf registration statement on Form S-3 (File No. 333-292680) and the related prospectus, as supplemented by a prospectus supplement dated March 24, 2026 (the “Registration Statement”) and filed with the Securities and Exchange Commission on such date pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”).

     

    Pursuant to the ATM Agreement, A.G.P. will use commercially reasonable efforts consistent with their normal trading and sales practices, applicable state and federal law, rules and regulations and rules of the Nasdaq Capital Markt to sell the Placement Shares in sales deemed to be “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act, including sales made directly on or through the Nasdaq Capital Market. If agreed to in a separate terms agreement, the Company may sell Placement Shares to A.G.P. as principal, at a purchase price agreed upon by A.G.P. and the Company. A.G.P. may also sell Placement Shares in negotiated transactions with the Company’s prior approval. The offer and sale of the Placement Shares pursuant to the ATM Agreement will terminate upon the earlier of (a) the issuance and sale of all of the Placement Shares subject to the ATM Agreement or (b) the termination of the ATM Agreement by A.G.P. or the Company pursuant to the terms thereof. The Company has no obligation to sell any of the Placement Shares, and may at any time suspend offers under the Agreement or terminate the Agreement.

     

    The Company has agreed to pay A.G.P. a commission of 3.0% of the aggregate gross proceeds from any Placement Shares sold by A.G.P. and to provide A.G.P. with customary indemnification and contribution rights, including for liabilities under the Securities Act. The Company also will reimburse A.G.P. for certain specified expenses in connection with entering into the ATM Agreement. The ATM Agreement contains customary representations and warranties and conditions to the placements of the Placement Shares pursuant thereto. The Sales Agent’s obligations to sell the Placement Shares under the Sales Agreement is subject to satisfaction of certain conditions, and other customary closing conditions.

     

    The foregoing summary of the ATM Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the ATM Agreement, which is attached as an exhibit to the Registration Statement and incorporated by reference into this Item 1.01.

     

    This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Placement Shares, nor shall there be any offer, solicitation, or sale of the Placement Shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    At the Company’s Special Meeting of Stockholders held on March 24, 2026 (the “Special Meeting”), two proposals were submitted to the Company’s stockholders. The final voting results were as follows:

     

    Proposal 1

     

    The Company’s stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(b), the issuance of the Company’s common stock upon conversion of Series A Convertible Preferred Stock and/or the exercise of warrants pursuant to the Company’s securities purchase agreement, dated January 27, 2026, with several purchasers (the “Issuance Proposal”).

     

    For   Against   Abstain   Broker Non-Votes
    2,758,323   97,941   12,372   0

     

    Proposal 2

     

    The Company’s stockholders approved the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Issuance Proposal. Adjournment of the Special Meeting was deemed not necessary, because there were sufficient votes at the time of the Special Meeting to approve the Issuance Proposal.

     

    For   Against   Abstain   Broker Non-Votes
    2,739,924   116,691   12,021   0

     

    Exhibit No.   Description
         
    1.1   Sales Agreement by and between Cingulate Inc. and A.G.P. / Alliance Global Partners dated March 24, 2026
    5.1   Opinion of Lowenstein Sandler LLP
    99.1   Consent of Lowenstein Sandler LLP (included in Exhibit 5.1)
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      CINGULATE INC.
         
    Dated: March 24, 2026 By: /s/ Shane J. Schaffer
      Name: Shane J. Schaffer
      Title: Chief Executive Officer

     

     

    Get the next $CING alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CING

    DatePrice TargetRatingAnalyst
    1/10/2025$12.00Buy
    ROTH MKM
    12/22/2023Buy → Hold
    Laidlaw
    1/20/2022$8.50Buy
    Laidlaw & Co.
    1/11/2022$9.00Buy
    Aegis Capital
    More analyst ratings

    $CING
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP and CFO Callahan Jennifer L. bought $24,515 worth of shares (4,864 units at $5.04), increasing direct ownership by 2,494% to 5,059 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Schaffer Shane J. bought $34,317 worth of shares (6,809 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:19 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Werth Peter J. bought $98,053 worth of shares (19,455 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and CSO Silva Raul R. was granted 4,526 shares and covered exercise/tax liability with 1,828 shares, increasing direct ownership by 139% to 4,645 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    3/11/26 8:13:31 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CLO and CCO Patel Nilay Dahyabhai was granted 5,475 shares and covered exercise/tax liability with 2,086 shares (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    3/11/26 8:13:27 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Schaffer Shane J. was granted 6,862 shares and covered exercise/tax liability with 2,959 shares, increasing direct ownership by 2,256% to 4,076 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    3/11/26 8:13:30 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    SEC Filings

    View All

    SEC Form EFFECT filed by Cingulate Inc.

    EFFECT - Cingulate Inc. (0001862150) (Filer)

    3/25/26 12:15:14 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders

    8-K - Cingulate Inc. (0001862150) (Filer)

    3/24/26 5:14:49 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Cingulate Inc.

    424B3 - Cingulate Inc. (0001862150) (Filer)

    3/24/26 5:13:25 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    KANSAS CITY, Kan., March 18, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended December 31, 2025, and provided a corporate update. Highlights include recent U.S. and European patent developments, the closing of a $12 million private investment, and the acceptance of a New Drug Application (NDA) for its lead candidate, CTx-1301 (dexmethylphenidate HCl). Cingulate CEO Shane J. Schaffer stated, "Cingulate delivered on key inflection points throughout 2025 and this continues i

    3/18/26 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

    KANSAS CITY, Kan., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced the successful closing of a $12 million private investment in public equity (PIPE) financing, led by certain affiliates of Falcon Creek Capital Advisor LLC ("Falcon Creek Capital"). "This long-term financing from life science–focused institutional investors represents strong validation of our strategy, our technology, and the significant commercial opportunity ahead. The transaction included insider participation underscoring our confidence in the value we are building and our commitment to sta

    2/17/26 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build a pipeline of next-generation products, today announced financial results for the quarter ended September 30, 2025, and provided recent corporate highlights. Recent Highlights (Post-Q3) FDA Accepts NDA for CTx-1301; PDUFA Date Set for May 31, 2026In October of 2025, the U.S. Food and Drug Administration (FDA) accepted Cingulate's New Drug Application

    11/13/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Cingulate with a new price target

    ROTH MKM initiated coverage of Cingulate with a rating of Buy and set a new price target of $12.00

    1/10/25 7:39:52 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate downgraded by Laidlaw

    Laidlaw downgraded Cingulate from Buy to Hold

    12/22/23 7:22:08 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Laidlaw & Co. initiated coverage on Cingulate with a new price target

    Laidlaw & Co. initiated coverage of Cingulate with a rating of Buy and set a new price target of $8.50

    1/20/22 9:15:46 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Leadership Updates

    Live Leadership Updates

    View All

    Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build a pipeline of next-generation products, today announced financial results for the quarter ended September 30, 2025, and provided recent corporate highlights. Recent Highlights (Post-Q3) FDA Accepts NDA for CTx-1301; PDUFA Date Set for May 31, 2026In October of 2025, the U.S. Food and Drug Administration (FDA) accepted Cingulate's New Drug Application

    11/13/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301

    Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate's transition toward commercialization pending FDA approval Company also strengthens its cash position by completing a $6 million financing KANSAS CITY, Kan., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-delivery platform, today announced the appointment of Bryan Downey as Chief Commercial Officer, following the U.S. Food and Drug Administration's (FDA) acceptance of Cingulate's New Drug Application (ND

    11/10/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application

    KANSAS CITY, Kan., July 09, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, has named Nilay Patel, JD, as Chief Legal Officer. Patel's appointment comes as Cingulate plans to submit a new drug application to the FDA in coming weeks for its lead asset CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Mr. Patel brings more than two decades of legal and compliance leadership in the pharmaceutical industry, having advised companies across

    7/9/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Financials

    Live finance-specific insights

    View All

    Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

    Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026 KANSAS CITY, Kan., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended June 30, 2025, and provided recent highlights. Recent Highlights: On July 31, 2025, Cingulate submitted its NDA to the FDA for CTx-1301, a novel, extended-release tablet formulation

    8/19/25 8:45:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

    Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone) KANSAS CITY, Kan., May 08, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended March 31, 2025, and provided a clinical and business update. Highlights include the completion of the Pre-NDA meeting for CTx-1301 and grant received to accelerate

    5/8/25 4:30:00 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

    KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three months ended September 30, 2024, and provided a clinical and business update. "The capital raised this quarter has allowed us to focus on advancing the remaining activities required for NDA submission of our lead ADHD asset, CTx-1301, targeted for mid 2025," said Cingulate Chairman and CEO Shane J. Schaffer. "The granting of European patents for CTx-1301 in up to

    11/7/24 7:30:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cingulate Inc.

    SC 13G/A - Cingulate Inc. (0001862150) (Subject)

    11/14/24 7:21:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cingulate Inc.

    SC 13D/A - Cingulate Inc. (0001862150) (Subject)

    8/30/24 6:00:22 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cingulate Inc.

    SC 13D/A - Cingulate Inc. (0001862150) (Subject)

    8/20/24 7:00:06 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care